Back to results
US 2024/0392002 A1Published application
Anti-ror antibody constructs
AssigneeExelixis, Inc.
InventorsLucas BAILEY, Qufei LI, Malgorzata Agnieszka NOCULA-LUGOWSKA, Bryan GLASER
Life of this patent
Estimating the term…
Abstract
Anti-ROR antibody constructs, pharmaceutical compositions comprising the constructs, and methods of use thereof are presented.
Claims39
(canceled)
A tyrosine-protein kinase transmembrane receptor (ROR) binding molecule, the ROR antigen binding molecule comprising
- a first antigen binding site specific for a ROR antigen, wherein the first antigen binding site comprises an antibody heavy chain variable (VH) region, and an antibody light chain variable (VL) region, wherein the VH region comprises a VH CDR1, a VH CDR2, and a VH CDR3 as set forth in the amino acid sequence of SEQ ID NO:
- 104, and the VL region comprises a VL CDR1, a VL CDR2, and a VL CDR3 as set forth in the amino acid sequence of SEQ ID NO:
- 100.
(canceled)
6-8. (canceled)
16-18. (canceled)
22-65. (canceled)
72-156. (canceled)
161-162. (canceled)
Dependencies are inferred from the claim text.